Phase IIa Proof of Concept, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of the Combination M5717 Plus Pyronaridine Administered Once Daily for 1 or 2 Days to Adults and Adolescents With Acute Uncomplicated Plasmodium Falciparum Malaria (CAPTURE 1)
Latest Information Update: 30 Sep 2025
At a glance
- Drugs Cabamiquine (Primary) ; Artesunate/pyronaridine; Pyronaridine
- Indications Malaria
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms CAPTURE 1
- Sponsors Merck KGaA
Most Recent Events
- 27 Aug 2025 Number of Arms changed from 3 to 2. Active Comparator arm Pyronaridine-artesunate has been removed from study protocol. Primary and secondary outcome measured amended.
- 03 Jan 2025 Status changed from active, no longer recruiting to completed.
- 14 Aug 2024 Planned End Date changed from 18 Sep 2024 to 1 Dec 2024.